KRAS and colorectal cancer: For example, Bardelli and colleagues have demonstrated that KRAS mutant sub-clones of colorectal cancers are more sensitive to withdrawal of an EGFR monoclonal antibody-based regimen such as cetuximab than are their wildtype counterparts.